Toll-like receptor 8 (TLR8), partial, human, recombinant

Toll-like receptor 8 (TLR8), partial, human, recombinant
Artikelnummer Größe Datenblatt Manual SDB Lieferzeit Menge Preis
CSB-YP023607HU.20 20 µg -

10 - 14 Werktage*

235,00 €
CSB-YP023607HU.100 100 µg -

10 - 14 Werktage*

424,00 €
CSB-YP023607HU.1 1 mg -

10 - 14 Werktage*

1.749,00 €
 
Organism: Homo sapiens (Human). Source: Yeast. Expression Region: 27-827aa. Protein Length:... mehr
Produktinformationen "Toll-like receptor 8 (TLR8), partial, human, recombinant"
Organism: Homo sapiens (Human). Source: Yeast. Expression Region: 27-827aa. Protein Length: partial. Tag Info: N-terminal 6xHis-tagged. Target Protein Sequence: EENFSRSYPC DEKKQNDSVI AECSNRRLQE VPQTVGKYVT ELDLSDNFIT HITNESFQGL QNLTKINLNH NPNVQHQNGN PGIQSNGLNI TDGAFLNLKN LRELLLEDNQ LPQIPSGLPE SLTELSLIQN NIYNITKEGI SRLINLKNLY LAWNCYFNKV CEKTNIEDGV FETLTNLELL SLSFNSLSHV PPKLPSSLRK LFLSNTQIKY ISEEDFKGLI NLTLLDLSGN CPRCFNAPFP CVPCDGGASI NIDRFAFQNL TQLRYLNLSS TSLRKINAAW FKNMPHLKVL DLEFNYLVGE IASGAFLTML PRLEILDLSF NYIKGSYPQH INISRNFSKL LSLRALHLRG YVFQELREDD FQPLMQLPNL STINLGINFI KQIDFKLFQN FSNLEIIYLS ENRISPLVKD TRQSYANSSS FQRHIRKRRS TDFEFDPHSN FYHFTRPLIK PQCAAYGKAL DLSLNSIFFI GPNQFENLPD IACLNLSANS NAQVLSGTEF SAIPHVKYLD LTNNRLDFDN ASALTELSDL EVLDLSYNSH YFRIAGVTHH LEFIQNFTNL KVLNLSHNNI YTLTDKYNLE SKSLVELVFS GNRLDILWND DDNRYISIFK GLKNLTRLDL SLNRLKHIPN EAFLNLPASL TELHINDNML KFFNWTLLQQ FPRLELLDLR GNKLLFLTDS LSDFTSSLRT LLLSHNRISH LPSGFLSEVS SLKHLDLSSN LLKTINKSAL ETKTTTKLSM LELHGNPFEC TCDIGDFRRW MDEHLNVKIP RLVDVICASP GDQRGKSIVS LELTTCVSDV T. Purity: Greater than 90% as determined by SDS-PAGE. Endotoxin: Not test. Biological Activity: n/a. Form: Liquid or Lyophilized powder. Buffer: If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol. If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0. Reconstitution: We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20 °C/-80 °C. Our default final concentration of glycerol is 50%. Customers could use it as reference. Storage: The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself. Generally, the shelf life of liquid form is 6 months at -20 °C/-80 °C. The shelf life of lyophilized form is 12 months at -20 °C/-80 °C. Notes: Repeated freezing and thawing is not recommended. Store working aliquots at 4 °C for up to one week. Relevance: Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response. Reference: The DNA sequence of the human X chromosome.Ross M.T., Grafham D.V., Coffey A.J., Scherer S., McLay K., Muzny D., Platzer M., Howell G.R., Burrows C., Bird C.P., Frankish A., Lovell F.L., Howe K.L., Ashurst J.L., Fulton R.S., Sudbrak R., Wen G., Jones M.C. , Hurles M.E., Andrews T.D., Scott C.E., Searle S., Ramser J., Whittaker A., Deadman R., Carter N.P., Hunt S.E., Chen R., Cree A., Gunaratne P., Havlak P., Hodgson A., Metzker M.L., Richards S., Scott G., Steffen D., Sodergren E., Wheeler D.A., Worley K.C., Ainscough R., Ambrose K.D., Ansari-Lari M.A., Aradhya S., Ashwell R.I., Babbage A.K., Bagguley C.L., Ballabio A., Banerjee R., Barker G.E., Barlow K.F., Barrett I.P., Bates K.N., Beare D.M., Beasley H., Beasley O., Beck A., Bethel G., Blechschmidt K., Brady N., Bray-Allen S., Bridgeman A.M., Brown A.J., Brown M.J., Bonnin D., Bruford E.A., Buhay C., Burch P., Burford D., Burgess J., Burrill W., Burton J., Bye J.M., Carder C., Carrel L., Chako J., Chapman J.C., Chavez D., Chen E., Chen G., Chen Y., Chen Z., Chinault C., Ciccodicola A., Clark S.Y., Clarke G., Clee C.M., Clegg S., Clerc-Blankenburg K., Clifford K., Cobley V., Cole C.G., Conquer J.S., Corby N., Connor R.E., David R., Davies J., Davis C., Davis J., Delgado O., Deshazo D., Dhami P., Ding Y., Dinh H., Dodsworth S., Draper H., Dugan-Rocha S., Dunham A., Dunn M., Durbin K.J., Dutta I., Eades T., Ellwood M., Emery-Cohen A., Errington H., Evans K.L., Faulkner L., Francis F., Frankland J., Fraser A.E., Galgoczy P., Gilbert J., Gill R., Gloeckner G., Gregory S.G., Gribble S., Griffiths C., Grocock R., Gu Y., Gwilliam R., Hamilton C., Hart E.A., Hawes A., Heath P.D., Heitmann K., Hennig S., Hernandez J., Hinzmann B., Ho S., Hoffs M., Howden P.J., Huckle E.J., Hume J., Hunt P.J., Hunt A.R., Isherwood J., Jacob L., Johnson D., Jones S., de Jong P.J., Joseph S.S., Keenan S., Kelly S., Kershaw J.K., Khan Z., Kioschis P., Klages S., Knights A.J., Kosiura A., Kovar-Smith C., Laird G.K., Langford C., Lawlor S., Leversha M., Lewis L., Liu W., Lloyd C., Lloyd D.M., Loulseged H., Loveland J.E., Lovell J.D., Lozado R., Lu J., Lyne R., Ma J., Maheshwari M., Matthews L.H., McDowall J., McLaren S., McMurray A., Meidl P., Meitinger T., Milne S., Miner G., Mistry S.L., Morgan M., Morris S., Mueller I., Mullikin J.C., Nguyen N., Nordsiek G., Nyakatura G., O'dell C.N., Okwuonu G., Palmer S., Pandian R., Parker D., Parrish J., Pasternak S., Patel D., Pearce A.V., Pearson D.M., Pelan S.E., Perez L., Porter K.M., Ramsey Y., Reichwald K., Rhodes S., Ridler K.A., Schlessinger D., Schueler M.G., Sehra H.K., Shaw-Smith C., Shen H., Sheridan E.M., Shownkeen R., Skuce C.D., Smith M.L., Sotheran E.C., Steingruber H.E., Steward C.A., Storey R., Swann R.M., Swarbreck D., Tabor P.E., Taudien S., Taylor T., Teague B., Thomas K., Thorpe A., Timms K., Tracey A., Trevanion S., Tromans A.C., d'Urso M., Verduzco D., Villasana D., Waldron L., Wall M., Wang Q., Warren J., Warry G.L., Wei X., West A., Whitehead S.L., Whiteley M.N., Wilkinson J.E., Willey D.L., Williams G., Williams L., Williamson A., Williamson H., Wilming L., Woodmansey R.L., Wray P.W., Yen J., Zhang J., Zhou J., Zoghbi H., Zorilla S., Buck D., Reinhardt R., Poustka A., Rosenthal A., Lehrach H., Meindl A., Minx P.J., Hillier L.W., Willard H.F., Wilson R.K., Waterston R.H., Rice C.M., Vaudin M., Coulson A., Nelson D.L., Weinstock G., Sulston J.E., Durbin R.M., Hubbard T., Gibbs R.A., Beck S., Rogers J., Bentley D.R.Nature 434:325-337(2005). Function: Key component of innate and adaptive immunity. TLRs (Toll-like receptors) control host immune response against pathogens through recognition of molecular patterns specific to microorganisms. Acts via MYD88 and TRAF6, leading to NF-kappa-B activation, cytokine secretion and the inflammatory response.
Schlagworte: TLR8, CD288, Toll-like receptor 8, Recombinant Human Toll-like receptor 8 (TLR8), partial
Hersteller: Cusabio
Hersteller-Nr: YP023607HU

Eigenschaften

Anwendung: Activity not tested
Konjugat: No
Wirt: Yeast
Spezies-Reaktivität: human
MW: 93.5 kD
Reinheit: >90% (SDS-PAGE)

Handhabung & Sicherheit

Lagerung: -20°C
Versand: +4°C (International: +4°C)
Achtung
Nur für Forschungszwecke und Laboruntersuchungen: Nicht für die Anwendung im oder am Menschen!
Hier folgen Informationen zur Produktreferenz. mehr
Hier kriegen Sie ein Zertifikat
oder , um Analysenzertifikate anzufordern.
Bewertungen lesen, schreiben und diskutieren... mehr
Kundenbewertungen für "Toll-like receptor 8 (TLR8), partial, human, recombinant"
Bewertung schreiben
oder , um eine Produktbewertung abzugeben.
Zuletzt angesehen